Using Nasal High Flow From Birth in Premature Infants - a Pilot Study

NCT ID: NCT01991886

Last Updated: 2016-08-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-31

Study Completion Date

2015-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Recent large studies have shown that not all premature babies need to be intubated (have a breathing tube inserted) and ventilated, nor do they all need to be given lung surfactant routinely. Those studies showed that even very small babies can be safely supported using nasal Continuous Positive Airway Pressure (nCPAP) which is applied tightly to the nose using nasal prongs. This is a type of noninvasive ventilation (NIV) so that the babies continue to breath, albeit with additional support to reduce their work of breathing. However nCPAP has some drawbacks, including that it can cause skin damage to the nose, and that the heating and humidification of the gas is not always sufficient. We have been using, for over 5 years, a different system to support babies after routine intubation. This is another type of noninvasive ventilation called nasal High Flow (nHF) for which we use a Vapotherm Precision Flow device. Published trials show that it is at least as effective as nCPAP to provide NIV and to prevent the subsequent need for intubation and/or surfactant. However nHF is superior to nCPAP in respect it does not cause nose damage and its heating and humidification is excellent. This pilot study aims to describe and evaluate the use of nHF, using a standard commercially available system (Precision Flow, Vapotherm Inc.), from birth, in babies born less than 30 completed weeks gestation, with a view to avoiding intubation and ventilation. This study is important to establish the feasibility of using nHF immediately after birth.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

We propose to pilot the use of this mobile nHF unit, using the Vapotherm Precision Flow device, in the premature population of babies who would normally be either intubated and given surfactant routinely, or be maintained on nCPAP until arrival on the Neonatal Intensive Care Unit (NICU) then transferred onto nHF. Parents will be informed about the pilot and their permission will be sought. We aim to recruit 40 babies less than 30 weeks gestation.

The reason for undertaking a pilot study of this nature is to establish feasibility and proof of concept. It is not designed to be compared to using nCPAP to stabilise babies immediately after birth (although that will be the next and logical progression if this proves to be a feasible technique).

The hypothesis is that using nHF to stabilise babies immediately after birth will confer the same advantages as using nCPAP to stabilise babies in this way, which has been demonstrated in the worldwide literature. For units such as ours who use nHF in preference to nCPAP, this will be an important step in further defining the management of these babies after birth. There is evidence that nHF is at least as good as nCPAP in preventing intubation and reducing lung disease, and it may also offer additional advantages from humidification and reduction in nasal trauma.

The major challenge for this pilot project will be to identify eligible deliveries in a timely manner to ensure that a suitable member of staff is available to speak to parents and gain consent.

Once a delivery has been identified and the parents have agreed to take part, then the following process will take place to manage the newborn baby.

Check the mobile nHF unit

* The mobile nHF unit should be kept plugged in so that the uninterruptable power supply (UPS) is fully charged
* To use it, unplug it to check that the UPS is functioning (green lights indicate full charge), set up a Vapotherm circuit(as per normal routine) and start the machine running on UPS power supply.
* Gas supply should be from the cylinders to check that the pressures are 50bar in both air and oxygen cylinders
* Set the temperature to 37 degrees Celsius
* Once running, turn the unit off if not immediately needed or plug into the mains power and gas(es) where available to conserve gas. The unit can be run on a flow of 1 litre/minute whilst "ticking over" to conserve cylinder gas if needed.
* The prongs should be attached to the circuit.

Once the baby is born

* Place the baby in a polythene bag (as per normal practice)
* Ensure the baby is breathing. If not, or the baby is bradycardic, then normal resuscitation measures should be applied. It will only be appropriate to apply the mobile nHF if the baby is breathing and is clinically stable.
* Once the baby is born, increase the flow to 6 litres/min
* If the baby is breathing then apply the nHF prongs and observe carefully
* Suction should only be applied gently, if needed to remove excessive secretions in the mouth and throat. Babies on high flow will often "blow bubbles" and there may be lung fluid in the throat, but suction should not be vigorous
* Apply a saturation monitor (as per normal practice) to check Heart Rate (HR) and Oxygen Saturation (SaO2).
* Dry the baby's face sufficiently to be able to apply duoderm dressing to stick down the prongs to the cheeks.
* Observe the baby carefully, ensure attention to thermal care and inform the parents about progress.
* As soon as the baby appears stable, move to NICU as per normal practice

Transfer to NICU

* Two people are needed to effect the transfer from labour ward/theatre to NICU, one to move the mobile nHF and one to move the resuscitaire.
* On arrival in NICU, plug the mobile nHF into gas and power supplies (switch the manifold over)
* Ensure that there is a second, cotside Vapotherm (empty) unit
* Leave the baby in the resuscitaire and check the admission temperature.
* Stop the mobile nHF, remove the cartridge and place it into the cotside Vapotherm unit. Start it running, it should run straight away. Ensure that the correct temperature, flow and Fraction Of Inspired Oxygen (FiO2) are set
* This process takes less than 20 seconds and as the baby is breathing will not be detrimental
* Transfer the baby into the incubator and commence normal admission practices
* Document the resuscitation clearly in the baby's notes

Cleaning and charging the mobile nHF

o Remove the mobile nHF, clean the Vapotherm Precision flow nHF unit. Ensure the cylinders are switched off and plug into the wall to recharge the UPS.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Premature Birth

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

nasal High Flow applied

Application of nasal High Flow 6-7l/min via nasal prongs after birth using a mobile Vapotherm Precision Flow device

Group Type EXPERIMENTAL

Vapotherm Precision Flow

Intervention Type DEVICE

Application of nasal High Flow using 6-7 l/min delivered by nasal prongs from birth

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vapotherm Precision Flow

Application of nasal High Flow using 6-7 l/min delivered by nasal prongs from birth

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

nasal High Flow device nasal heated humidified high flow cannula

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Parental consent
* 24+0 to 30+0 weeks(agreed dates) gestation born alive
* Breathing spontaneously at birth or soon after with minimal resuscitation
* Oxygen saturations \>90% by 5 minutes

Exclusion Criteria

* No parental consent
* Born in poor condition and unlikely to survive
* Needing resuscitation including intubation and/or chest compressions
* Not breathing and thus needing intubation
* Oxygen saturations \<90% by 5 minutes
* \<24 weeks gestation
* \>30 weeks gestation
Minimum Eligible Age

24 Weeks

Maximum Eligible Age

30 Weeks

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ashford and St. Peter's Hospitals NHS Trust

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Peter Dr Reynolds, PhD

Role: PRINCIPAL_INVESTIGATOR

Ashford and St. Peter's Hospitals NHS Foundation Trust

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Neonatal ICU, St Peter's Hospital

Chertsey, Surrey, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Reynolds P, Leontiadi S, Lawson T, Otunla T, Ejiwumi O, Holland N. Stabilisation of premature infants in the delivery room with nasal high flow. Arch Dis Child Fetal Neonatal Ed. 2016 Jul;101(4):F284-7. doi: 10.1136/archdischild-2015-309442. Epub 2016 Jan 5.

Reference Type DERIVED
PMID: 26733541 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

131594

Identifier Type: OTHER

Identifier Source: secondary_id

2013PR01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.